Polymarket puts 67% odds on AI-designed skin cancer vaccine approval by end of 2027
Polymarket · x · 2026-10-20
Polymarket traders give 67% odds that the FDA approves a skin cancer vaccine by end of 2027, with over $181K traded. The main driver is positive Phase 3 results for Moderna and Merck's personalized mRNA neoantigen vaccine intismeran autogene: the INTerpath-001 trial showed statistically significant improvements in recurrence-free and distant metastasis-free survival versus Keytruda alone — the first late-stage success for an individualized mRNA cancer vaccine. The platform sequences tumor mutations to encode up to 34 neoantigens into synthetic mRNA, complementing PD-1 blockade. Separate news: a biotech startup treated a human patient with AI-designed viruses for the first time, targeting antibiotic-resistant E. coli.
More from Apps
- Tip: run truly important non-coding work through Claude and ChatGPT at max reasoning — iruletheworldmo · 2026-10-20
- Okara launches a LinkedIn Influencer Agent that finds creators and runs campaigns — sahilypatel · 2026-10-20
- 300M People a Week Ask ChatGPT Health Questions: OpenAI's Karan Singhal on AI Medicine — a16z · 2026-10-20
- Grok Bot ships wave of updates: voice calls, X DMs, connectors and more — mattyp · 2026-10-20
- threepointone ships interactive installation "The City That Remembers" at Connect expo — threepointone · 2026-10-20
- Designer builds AI-powered site mapping 100+ horror/sci-fi films to social traumas — AI_Andrew · 2026-10-20